Alysena 28 Birth Control Recall Issued Due to Risk of Unwanted Pregnancy

|

A packaging error may have left many Canadian women taking Alysena-28 birth control pills unprotected from pregnancy. 

An Alysena 28 birth control pill recall has been issued after it was determined that some packages may contain two weeks’ worth of placebo tablets and two weeks of birth control pills by mistake.

Apotex, the distributor issued a recall on April 9, but some women have complained that the company only informed distributors, and failed to inform consumers using the pills about the birth control recall.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

Initially, Apotex classified its actions as a voluntary Type II recall. However, Health Canada, the Canadian drug and health enforcement agency, upgraded the recall to Type I because some women take the pills because they cannot get pregnant due to medical reasons.

The Alysena 28 blister packs are supposed to contain 21 active ingredient pills and seven placebo pills. However, the recalled packets may contain 14 of each, reducing the effectiveness of the pills’ birth control effects. The recalled blister packs have a lot number of LF01899A and were distributed across Canada.

There were similar recalls for birth control pill manufacturing errors issued in the United States last year. In June, ten lots of Introvale birth control pills were recalled after a consumer discovered the placebo pills had been placed in the wrong row.

In February 2012, Glenmark Generics issued a norgestimate and ethinyl estradiol birth control recall, also due to packaging issues. A month before that, Pfizer recalled about one million packs of Lo/orval-28 and generic norgestrel birth control pills due to similar problems, where some blister packs in 28 different lots were identified as potentially containing the wrong number of pills and out of sequence tablets.

Apotex is recommending that women who believe they received and used one of the improperly packaged Alysena 28 blister packs use a non-hormonal method of contraception until they talk to their physician.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Image Credit: |



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A new lawsuit against Roblox alleges that the platform’s inadequate safety measures enabled multiple sexual predators to exploit a five-year-old girl.
Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.
Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.